Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: A cross sectional study on 142 patients

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Saidenberg Kermanac'h, Nathalie ^a,b,c   Semerano, Luca ^a,b,c   Nunes, Hilario ^c   Sadoun, Danielle ^c   Guillot, Xavier ^a,b,c   Boubaya, Marouane ^c   Naggara, Nicolas ^c   Valeyre, Dominique ^c   Boissier, Marie Christophe ^a,b,c  

^a MALIBUL and INSERM UMR1125   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; CORTICOSTEROID; CREATININE; OSTEOCALCIN; PARATHYROID HORMONE; PREDNISONE; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE FRAGILITY; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CALCIUM METABOLISM; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ELECTROLYTE DISTURBANCE; FEMALE; FRAGILITY FRACTURE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; SARCOIDOSIS; SPINE FRACTURE; SPINE RADIOGRAPHY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; BLOOD; BONE AND BONES; CALCIUM METABOLISM DISORDERS; COMPLICATION; CROSS-SECTIONAL STUDIES; HUMANS; METABOLISM; MIDDLE AGED; PILOT PROJECTS; PREVALENCE; RISK FACTORS; SPINAL FRACTURES;

BONE AND BONES; BONE DENSITY; CALCIUM; CALCIUM METABOLISM DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PILOT PROJECTS; PREVALENCE; RISK FACTORS; SARCOIDOSIS; SPINAL FRACTURES; VITAMIN D;

EID: 84898900009     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4519     Document Type: Article

References (34)

1. Goldring SR, Gravallese EM. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2000, 2:33-37. 10.1186/ar67, 129989, 11094416.
2. Confavreux CB, Chapurlat RD. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int 2011, 22:1023-1036. 10.1007/s00198-010-1462-4, 20959960.
3. Reichel H, Koeffer H, Barbers R, Norman AW. Regulation of 1,25-dihydroxyvitamin D production by cultured alveolar macrophages from normal human donors and from patient with pulmonary sarcoidosis. J Clin Endocrinol Metab 1987, 65:1201-1209. 10.1210/jcem-65-6-1201, 3119653.
4. Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax 1998, 53:425-429. 10.1136/thx.53.5.425, 1745206, 9708239.
5. Stern PH, De Olazabal J, Bell NH. Evidence for abnormal regulation of circulating 1 alpha,25-dihydroxyvitamin D in patients with sarcoidosis and normal calcium metabolism. J Clin Invest 1980, 66:852-855. 10.1172/JCI109924, 371661, 7419722.
6. Rizzato G, Montemurro L. Reversibility of exogenous corticosteroid-induced bone loss. Eur Respir J 1993, 6:116-119.
7. Rizzato G, Fraioli P. Natural and corticosteroid-induced osteoporosis in sarcoidosis: prevention, treatment, follow up and reversibility. Sarcoidosis 1990, 7:89-92.
8. Rizzato G, Tosi G, Mella C, Montemurro L, Zanni D, Sisti S. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis 1988, 5:93-98.
9. Sipah S, Tuzun S, Ozaras R, Calis HT, Ozaras N, Tuzun F, Karayel T. Bone mineral density in women with sarcoidosis. J Bone Miner Metab 2004, 22:48-52. 10.1007/s00774-003-0448-0, 14691687.
10. Adler RA, Funkhouser HL, Petkov VI, Berger MM. Glucocorticoid-induced osteoporosis in patient with sarcoidosis. Am J Med Sci 2003, 325:1-6. 10.1097/00000441-200301000-00001, 12544077.
11. Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, Rizzato G. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Ann Ital Med Int 1990, 5:164-168.
12. Rizzato G, Tosi G, Mella C, Zanni D, Sisti S, Loglisci T. Researching osteoporosis in prednisone treated sarcoid patients. Sarcoidosis 1987, 4:45-48.
13. Heijckmann AC, Drent M, Dumitrescu B, De Vries J, Nieuwenhuijzen Kruseman AC, Wolffenbuttel BH, Geusens P, Huijberts MS. Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study. Osteopors Int 2008, 19:839-847.
14. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999, 160:736-755.
15. Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C, Bellony R, Dubreuil A. Evaluation of the calcium content of diet by frequential self-questionnaire. Rev Rhum Mal Osteoartic 1991, 58:99-103.
16. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8:1137-1148.
17. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96:53-58. 10.1210/jc.2010-2704, 3046611, 21118827.
18. Kavathia D, Buckley JD, Rao D, Rybicki B, Burke R. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med 2010, 104:564-570. 10.1016/j.rmed.2009.12.004, 20071158.
19. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010, 303:815-822.
20. Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Almås B, Jorde R. The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal. Osteoporos Int 2012, 23:201-211. 10.1007/s00198-011-1752-5, 21909730.
21. Ensrud KE, Ewing SK, Fredman L, Hochberg MC, Cauley JA, Hillier TA, Cummings SR, Yaffe K, Cawthon PM, Study of Osteoporotic Fractures Research Group Circulating 25-hydroxyvitamin D levels and frailty status in older women. J Clin Endocrinol Metab 2010, 95:5266-5273. 10.1210/jc.2010-2317, 2999979, 21131545, Study of Osteoporotic Fractures Research Group.
22. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, Misselwitz J, Klaus G, Kuwertz-Bröking E, Fehrenbach H, Wingen AM, Güran T, Hoenderop JG, Bindels RJ, Prosser DE, Jones G, Konrad M. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011, 365:410-421. 10.1056/NEJMoa1103864, 21675912.
23. Dawson-Hughes B, Harris SS. High-dose vitamin D supplementation: too much of a good thing?. JAMA 2010, 303:1861-1862. 10.1001/jama.2010.598, 20460627.
24. Ueno Y, Shinki T, Nagai Y, Murayama H, Fujii K, Suda T. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem 2003, 90:267-277. 10.1002/jcb.10623, 14505343.
25. Anderson PH, Iida S, Tyson JH, Turner AG, Morris HA. Bone CYP27B1 gene expression is increased with high dietary calcium and in mineralising osteoblasts. J Steroid Biochem Mol Biol 2010, 121:71-75. 10.1016/j.jsbmb.2010.03.021, 20236619.
26. Hamada K, Nagai S, Tsutsumi T, Izumi T. Bone mineral density and vitamin D in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999, 16:219-223.
27. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477-501. 10.1210/edrv.22.4.0437, 11493580.
28. Lips P. The relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 2007, 22:1668-1671. 10.1359/jbmr.070716, 17645404.
29. Welsh P, Peters MJ, McInnes IB, Lems WF, Lips PT, McKellar G, Knox S, Michael Wallace A, Dijkmans BA, Nurmohamed MT, Sattar N. Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNFα blockade: results from a prospective cohort study. Ann Rheum Dis 2011, 70:1165-1167. 10.1136/ard.2010.137265, 21047908.
30. Bouvard B, Annweiler C, Sallé A, Beauchet O, Chappard D, Audran M, Legrand E. Extraskeletal effects of vitamin D: facts, uncertainties, and controversies. Joint Bone Spine 2011, 78:10-16. 10.1016/j.jbspin.2010.10.011, 21169046.
31. Baughman RP, Janovcik J, Ray M, Sweiss N, Lower EE. Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2013, 1:113-120.
32. van der Klift M, de Laet CE, McCloskey EV, Hofman A, Pols HA. The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res 2002, 17:1051-1056. 10.1359/jbmr.2002.17.6.1051, 12054160.
33. Siffledeen JS, Siminoski K, Jen H, Fedorak RN. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2007, 5:721-728. 10.1016/j.cgh.2007.02.024, 17482522.
34. Heijckmann AC, Huijberts MS, De Vries J, Menheere PP, Van Der Veer E, Kruseman AC, Wolffenbuttel BH, Geusens P, Drent M. Bone turnover and hip bone mineral density in patient with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2007, 24:51-58.